← Leaderboards
Silvia Fossati
New York University School Of Medicine
$5,961,731
Attributed
$6,191,809
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,191,809 · 4
By mechanism
R01$5,307,919 · 2
R21$460,157 · 1
P01$423,733 · 1
Top collaborators
- SãBastien HãBert2 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Efrat Levy$16,670,052
- Agueda Rostagno$1,841,326
- Antonio Convit$12,424,719
- Blas Frangione$6,920,422
- Josef Coresh$115,254,828
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposBrainPathway InteractionsMitochondrial DysfunctionEndothelial CellsCell DeathAmyloidosisCellular StressS DiseaseCellsFailureNeurovascularCerebral Amyloid AngiopathyBlood VesselsAmyloid Beta-ProteinFunctional DisorderDepositionAmyloidMouse ModelCessation Of LifeMediatingImpaired CognitionIn VitroCerebrum
Grant awards (19)
Vascular MicroRNA-212 in CAA and Alzheimer's disease$66,253
R21 · FY2024 · NS · contact PI
Targeting carbonic anhydrases in Alzheimer's disease$452,294
R01 · FY2023 · AG · contact PI
Vascular MicroRNA-212 in CAA and Alzheimer's disease$393,904
R21 · FY2023 · NS · contact PI
Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factors$560,647
R01 · FY2022 · NS · contact PI
Targeting carbonic anhydrases in Alzheimer's disease$452,294
R01 · FY2022 · AG · contact PI
Leveraging biomarkers for personalized treatment of alcohol use disorder comorbid with PTSD$93,561
P01 · FY2022 · AA · contact PI
Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factors$631,769
R01 · FY2021 · NS · contact PI
Targeting carbonic anhydrases in Alzheimer's disease$452,294
R01 · FY2021 · AG · contact PI
Leveraging biomarkers for personalized treatment of alcohol use disorder comorbid with PTSD$85,933
P01 · FY2021 · AA · contact PI
Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factors$667,330
R01 · FY2020 · NS · contact PI
Targeting carbonic anhydrases in Alzheimer's disease$480,580
R01 · FY2020 · AG · contact PI
Leveraging biomarkers for personalized treatment of alcohol use disorder comorbid with PTSD$85,933
P01 · FY2020 · AA · contact PI
Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factors$35,561
R01 · FY2020 · NS · contact PI
Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factors$560,647
R01 · FY2019 · NS · contact PI
Targeting carbonic anhydrases in Alzheimer's disease$460,376
R01 · FY2019 · AG · contact PI
Leveraging biomarkers for personalized treatment of alcohol use disorder comorbid with PTSD$77,458
P01 · FY2019 · AA · contact PI
Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factors$298,318
R01 · FY2018 · NS · contact PI
Potentiation of CAA-mediated endothelial dysfunction by cardiovascular risk factors$255,809
R01 · FY2018 · NS · contact PI
Leveraging biomarkers for personalized treatment of alcohol use disorder comorbid with PTSD$80,848
P01 · FY2018 · AA · contact PI